There's hope that this won't be an issue in the future: https://www.reviewofoptometry.com/news/article/eye-drop-for-presbyopia-moves-through-trials https://www

There's hope that this won't be an issue in the future: https://www.reviewofoptometry.com/news/article/eye-drop-for-presbyopia-moves-through-trials https://www.reviewofoptometry.com/news/article/eye-drop-for-... I've been following the development of this drug since before it was bought by Novartis. I was expecting the average results to get better along with the median, but perhaps the dosage just wasn't high enough in this trial.